[1]韦怡春,易秋艳.沙库巴曲缬沙坦对心力衰竭患者抑郁的影响[J].医学信息,2021,34(23):29-32.[doi:10.3969/j.issn.1006-1959.2021.23.008]
 WEI Yi-chun,YI Qiu-yan.Effect of Sacubitril Valsartan on Depression in Patients with Heart Failure[J].Medical Information,2021,34(23):29-32.[doi:10.3969/j.issn.1006-1959.2021.23.008]
点击复制

沙库巴曲缬沙坦对心力衰竭患者抑郁的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年23期
页码:
29-32
栏目:
综述
出版日期:
2021-12-01

文章信息/Info

Title:
Effect of Sacubitril Valsartan on Depression in Patients with Heart Failure
文章编号:
1006-1959(2021)23-0029-04
作者:
韦怡春易秋艳
(柳州市人民医院全科医学科,广西 柳州 545006)
Author(s):
WEI Yi-chunYI Qiu-yan
(Department of General Medicine,Liuzhou People’s Hospital,Liuzhou 545006,Guangxi,China)
关键词:
沙库巴曲缬沙坦血管紧张素受体脑啡肽酶抑制剂心力衰竭抑郁
Keywords:
Sakubatro valsartanAngiotensin receptor neprilysin inhibitorHeart failureDepression
分类号:
R541.6
DOI:
10.3969/j.issn.1006-1959.2021.23.008
文献标志码:
A
摘要:
心力衰竭是心血管疾病终末期的表现,其患病率及死亡率一直居高不下。沙库巴曲缬沙坦钠是血管紧张素受体脑啡肽酶抑制剂(ARNI)类药物,是新型心衰治疗药物,具有扩张血管、降低血压、促进尿钠排泄等作用,成为治疗心力衰竭的“基石”。抑郁是心血管疾病重要的危险因素及合并症,改善抑郁症状对心衰治疗有益处,目前有研究结果显示沙库巴曲缬沙坦可以改善心衰患者的抑郁症状。本文对沙库巴曲缬沙坦治疗心力衰竭的作用机制、改善抑郁的机制、研究进展等进行了综述,旨在提高临床对该药认识及对心衰合并抑郁的治疗有所了解。
Abstract:
Heart failure is a manifestation of the end-stage of cardiovascular disease, and its prevalence and mortality remain high. Salkubatrol valsartan sodium is an angiotensin receptor neprilysin inhibitor (ARNI) and a new therapeutic drug for heart failure, which can dilate blood vessels, reduce blood pressure and promote urinary sodium excretion, and has become the "cornerstone" for the treatment of heart failure. Depression is an important risk factor and complication of cardiovascular disease, improving depressive symptoms is beneficial to the treatment of heart failure, and current research results show that sacubitril valsartan can improve depressive symptoms in patients with heart failure. This paper reviews the mechanism of action of sacubitril valsartan in the treatment of heart failure, the mechanism of improving depression, and the research progress, in order to improve the clinical understanding of the drug and the treatment of heart failure complicated with depression.

参考文献/References:

[1]中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J].中国循环杂志,2020,35(9):833-854.[2]Rutledge T,Reis VA,Linke SE,et al.Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes[J].J Am Coll Cardiol,2006,48(8):1527-1537.[3]季俭,卢英民,王敏燕,等.老年心力衰竭病人不良心理状况及其相关危险因素分析[J].实用老年医学,2020,34(4):390-393.[4]梁玉兰,吕晓珍,张莹,等.住院老年心力衰竭患者抑郁障碍患病状况及影响因素初步分析[J].心肺血管病杂志,2019,38(5):476-479.[5]Daskalopoulou M,George J,Walters K,et al.Depression as a Risk Factor for the Initial Presentation of Twelve Cardiac, Cerebrovascular, and Peripheral Arterial Diseases: Data Linkage Study of 1.9 Million Women and Men[J].PLoS One,2016,11(4):e153838.[6]Laghrissi-Thode F,Wagner WR,Pollock BG,et al.Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease[J].Biol Psychiatry,1997,42(4):290-295.[7]Serebruany VL,Glassman AH,Malinin AI,et al.Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy[J].Circulation,2003,108(8):939-944.[8]Gimeno D,Kivimaki M,Brunner EJ,et al.Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study[J].Psychol Med,2009,39(3):413-423.[9]Kalogeropoulos A,Georgiopoulou V,Psaty BM,et al.Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study[J].J Am Coll Cardiol,2010,55(19):2129-2137.[10]Parissis JT,Farmakis D,Nikolaou M,et al.Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study[J].Eur J Heart Fail,2009,11(10):967-972.[11]Xiong GL,Prybol K,Boyle SH,et al.Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study[J].Psychosom Med,2015,77(7):808-815.[12]Gold PW,Machado-Vieira R,Pavlatou MG.Clinical and biochemical manifestations of depression:relation to the neurobiology of stress[J].Neural Plast,2015(2015):581976.[13]Redwine LS,Wirtz PH,Hong S,et al.Depression as a potential modulator of Beta-adrenergic-associated leukocyte mobilization in heart failure patients[J].J Am Coll Cardiol,2010,56(21):1720-1727.[14]Carney RM,Freedland KE.Depression and coronary heart disease[J].Nat Rev Cardiol,2017,14(3):145-155.[15]Walter FA,Gathright E,Redle JD,et al.Depressive Symptoms are Associated with Heart Rate Variability Independently of Fitness: A Cross-Sectional Study of Patients with Heart Failure[J].Ann Behav Med,2019,53(11):955-963.[16]Sbolli M,Fiuzat M,Cani D,et al.Depression and heart failure: the lonely comorbidity[J].Eur J Heart Fail,2020,22(11):2007-2017.[17]Miyoshi T,Nakamura K,Miura D,et al.Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats[J].Cardiol J,2019,26(5):575-583.[18]Sangaralingham SJ,Mckie PM,Ichiki T,et al.Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population[J].Hypertension,2015,65(6):1187-1194.[19]Schoenfeld HA,West T,Verghese PB,et al.The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-beta concentrations and clearance in the cynomolgus monkey[J].Toxicol Appl Pharmacol,2017(323):53-65.[20]程小兵.沙库巴曲缬沙坦治疗心力衰竭的作用机制、临床应用及指南推荐意见[J].实用心脑肺血管病杂志,2019,27(9):1-4.[21]Cacciatore F,Amarelli C,Maiello C,et al.Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure[J].J Affect Disord,2020(272):132-137.[22]Dereli S,Kilincel O,Cerik IB,et al.Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction[J].Acta Cardiol,2020,75(8):774-782.[23]Roques BP.Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins[J].Handb Exp Pharmacol,2018(247):53-70.[24]Maslov MY,Foianini S,Orlov MV,et al.A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload[J].J Card Fail,2018,24(11):773-782.[25]Carels RA.The association between disease severity, functional status, depression and daily quality of life in congestive heart failure patients[J].Qual Life Res,2004,13(1):63-72.[26]Vitale G,Romano G,Di Franco A,et al.Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction[J].J Clin Med,2019,8(2):262.[27]Jing W,Vaziri ND,Nunes A,et al.LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD[J].Am J Transl Res,2017,9(12):5473-5484.[28]Suematsu Y,Jing W,Nunes A,et al.LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease[J].J Card Fail,2018,24(4):266-275.

相似文献/References:

[1]熊鹏锋.沙库巴曲缬沙坦联合美托洛尔对青年扩张型心肌病患者心功能及预后的影响[J].医学信息,2022,35(20):80.[doi:10.3969/j.issn.1006-1959.2022.20.020]
 XIONG Peng-feng.Effect of Sacubitril Valsartan Combined with Metoprolol on Cardiac Function and Prognosis in Young Patients with Dilated Cardiomyopathy[J].Medical Information,2022,35(23):80.[doi:10.3969/j.issn.1006-1959.2022.20.020]
[2]袁 超.沙库巴曲缬沙坦联合比索洛尔治疗慢性心力衰竭的效果[J].医学信息,2020,33(19):135.[doi:10.3969/j.issn.1006-1959.2020.19.041]
 YUAN Chao.Effect of Sacubitril Valsartan Combined with Bisoprolol in the Treatment of Chronic Heart Failure[J].Medical Information,2020,33(23):135.[doi:10.3969/j.issn.1006-1959.2020.19.041]
[3]王晨青,李婧炜.沙库巴曲缬沙坦在心力衰竭中的应用现状[J].医学信息,2021,34(01):37.[doi:10.3969/j.issn.1006-1959.2021.01.011]
 WANG Chen-qing,LI Jing-wei.The Application Status of Sacubatril Valsartan in Heart Failure[J].Medical Information,2021,34(23):37.[doi:10.3969/j.issn.1006-1959.2021.01.011]
[4]龚殿炳.芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的临床效果及对心室重构的影响[J].医学信息,2023,36(23):99.[doi:10.3969/j.issn.1006-1959.2023.23.025]
 GONG Dian-bing.Clinical Effect of Qili Qiangxin Capsules Combined with Sacubitril Valsartan in Treatment of Chronic Heart Failure and its Effect on Ventricular Remodeling[J].Medical Information,2023,36(23):99.[doi:10.3969/j.issn.1006-1959.2023.23.025]
[5]葛文涛,程长生,胡成坤.强心贴联合沙库巴曲缬沙坦对慢性心力衰竭患者脑钠肽水平的影响[J].医学信息,2025,38(04):132.[doi:10.3969/j.issn.1006-1959.2025.04.024]
 GE Wentao,CHENG Changsheng,HU Chengkun.Effect of Qiangxin Paste Combined with Sacubitril Valsartan on Brain Natriuretic Peptide Level in Patients with Chronic Heart Failure[J].Medical Information,2025,38(23):132.[doi:10.3969/j.issn.1006-1959.2025.04.024]
[6]邱隆霞.沙库巴曲缬沙坦对射血分数保留心功能衰竭患者临床症状及心功能的影响[J].医学信息,2025,38(09):92.[doi:10.3969/j.issn.1006-1959.2025.09.017]
 QIU Longxia.Effect of Sacubitril/Valsartan on Clinical Symptoms and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction[J].Medical Information,2025,38(23):92.[doi:10.3969/j.issn.1006-1959.2025.09.017]
[7]刘文烜,胡 晋,钟小丽,等.沙库巴曲缬沙坦联合八段锦对心力衰竭合并室性心律失常的临床疗效研究[J].医学信息,2025,38(09):105.[doi:10.3969/j.issn.1006-1959.2025.09.020]
 LIU Wenxuan,HU Jin,ZHONG Xiaoli,et al.Study on the Clinical Effect of Sacubitril/Valsartan Combined with Baduanjin on Heart Failure Complicated with Ventricular Arrhythmia[J].Medical Information,2025,38(23):105.[doi:10.3969/j.issn.1006-1959.2025.09.020]
[8]刘红岳,杨培亮.新四联治疗心衰伴心脏扩大患者的临床效果及安全性分析[J].医学信息,2025,38(12):91.[doi:10.3969/j.issn.1006-1959.2025.12.018]
 LIU Hongyue,YANG Peiliang.Clinical Effect and Safety Analysis of New Quadruple Therapy in Patients with Heart Failure and Cardiac Enlargement[J].Medical Information,2025,38(23):91.[doi:10.3969/j.issn.1006-1959.2025.12.018]
[9]寇婵媛.沙库巴曲缬沙坦联合血液透析对慢性肾脏病患者炎症状态及骨代谢的影响[J].医学信息,2025,38(14):119.[doi:10.3969/j.issn.1006-1959.2025.14.023]
 KOU Chanyuan.Effect of Sacubitril Valsartan Combined with Hemodialysis on Inflammatory State and Bone Metabolism in Patients with Chronic Kidney Disease[J].Medical Information,2025,38(23):119.[doi:10.3969/j.issn.1006-1959.2025.14.023]
[10]唐 敏.新活素与沙库巴曲缬沙坦联合治疗对顽固性心衰患者左室射血分数及心血管不良事件的影响[J].医学信息,2026,39(02):96.[doi:10.3969/j.issn.1006-1959.2026.02.017]
 TANG Min.Effect of Combined Treatment of rhBNP and Sacubitril Valsartan on Left Ventricular Ejection Fraction and Cardiovascular Adverse Events in Patients with Refractory Heart Failure[J].Medical Information,2026,39(23):96.[doi:10.3969/j.issn.1006-1959.2026.02.017]
[11]李 龙,汪莲开.沙库巴曲缬沙坦在心力衰竭治疗中的应用[J].医学信息,2020,33(02):58.[doi:10.3969/j.issn.1006-1959.2020.02.016]
 LI Long,WANG Lian-kai.Application of Shakubatrivasartan in the Treatment of Heart Failure[J].Medical Information,2020,33(23):58.[doi:10.3969/j.issn.1006-1959.2020.02.016]

更新日期/Last Update: 1900-01-01